FIA
SMMT icon

FNY Investment Advisers’s Summit Therapeutics SMMT Stock Holding History

FNY Investment Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,100
Closed -$21.3K – 915
2024
Q3 		$24K Buy
+1,100
New +$15.4K 0.01% 376

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

FNY Investment Advisers's SMMT Position: Q4 2024 in Review

FNY Investment Advisers sold out of Summit Therapeutics (SMMT) in Q4 2024, closing a stake of 1,100 shares — an estimated $21.3K sold.

FNY Investment Advisers first reported a position in SMMT in Q3 2024 and held it in 1 quarter. The position peaked at $24K in Q3 2024. 203 funds tracked by Wall St. Rank hold SMMT as of Q4 2024.

  • FNY Investment Advisers reported no remaining Summit Therapeutics position as of Q4 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 1,100 Summit Therapeutics shares in Q4 2024, an estimated $21.3K.
  • FNY Investment Advisers first reported a position in Summit Therapeutics in Q3 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Summit Therapeutics position peaked at $24K in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2024.

Based on FNY Investment Advisers's 13F filing for Q4 2024, filed 13 Jan 2025.